Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
Rose AM, Nicolay N, Sandonis Martín V, Mazagatos C, Petrović G, Baruch J, Denayer S, Seyler L, Domegan L, Launay O, Machado A, Burgui C, Vaikutyte R, Niessen FA, Loghin II, Husa P, Aouali N, Panagiotakopoulos G, Tolksdorf K, Horváth JK, Howard J, Pozo F, Gallardo V, Nonković D, Džiugytė A, Bossuyt N, Demuyser T, Duffy R, Luong Nguyen LB, Kislaya I, Martínez-Baz I, Gefenaite G, Knol MJ, Popescu C, Součková L, Simon M, Michelaki S, Reiche J, Ferenczi A, Delgado-Sanz C, Lovrić Makarić Z, Cauchi JP, Barbezange C, Van Nedervelde E, O'Donnell J, Durier C, Guiomar R, Castilla J, Jonikaite I, Bruijning-Verhagen PC, Lazar M, Demlová R, Wirtz G, Amerali M, Dürrwald R, Kunstár MP, Kissling E, Bacci S, Valenciano M; I-MOVE-COVID-19 hospital study team; VEBIS hospital study team; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above). Rose AM, et al. Among authors: o donnell j, launay o. Euro Surveill. 2023 Nov;28(47):2300187. doi: 10.2807/1560-7917.ES.2023.28.47.2300187. Euro Surveill. 2023. PMID: 37997665 Free PMC article.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. de Bruyn G, et al. Among authors: launay o. EClinicalMedicine. 2023 Jul 22;62:102109. doi: 10.1016/j.eclinm.2023.102109. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37533419 Free PMC article.
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.
Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, Ajana F, Colin de Verdière N, Reynes J, Foubert V, Roman F, Devaster JM, Delfraissy JF, Aboulker JP; ANRS 151 HIFLUVAC Study Group and the French Clinical Vaccinology Network (Réseau National d'Investigation Clinique en Vaccinologie REIVAC). Launay O, et al. J Infect Dis. 2011 Jul 1;204(1):124-34. doi: 10.1093/infdis/jir211. J Infect Dis. 2011. PMID: 21628666 Free PMC article. Clinical Trial.
Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial.
Galgani I, Põder A, Jõgi R, Anttila VJ, Milleri S, Borobia AM, Launay O, Testa M, Casula D, Grassano L, Tasciotti A, Dozot M, Arora AK. Galgani I, et al. Among authors: launay o. Hum Vaccin Immunother. 2023 Dec 31;19(1):2187194. doi: 10.1080/21645515.2023.2187194. Epub 2023 Mar 28. Hum Vaccin Immunother. 2023. PMID: 36974988 Free PMC article. Clinical Trial.
Long Covid: a global health issue - a prospective, cohort study set in four continents.
Pazukhina E, Garcia-Gallo E, Reyes LF, Kildal AB, Jassat W, Dryden M, Holter JC, Chatterjee A, Gomez K, Søraas A, Puntoni M, Latronico N, Bozza FA, Edelstein M, Gonçalves BP, Kartsonaki C, Kruglova O, Gaião S, Chow YP, Doshi Y, Duque Vallejo SI, Ibáñez-Prada ED, Fuentes YV, Hastie C, O'Hara ME, Balan V, Menkir T, Merson L, Kelly S, Citarella BW, Semple MG, Scott JT, Munblit D, Sigfrid L; ISARIC Clinical Characterisation Group and ISARIC Global Covid-19 follow up working group. Pazukhina E, et al. BMJ Glob Health. 2024 Oct 21;9(10):e015245. doi: 10.1136/bmjgh-2024-015245. BMJ Glob Health. 2024. PMID: 39433402 Free PMC article.
Antibody Persistence and Risk of COVID-19 Infection: Insights from Modeling.
Coudeville L, Konate E, Simon T, de Lamballerie X, Patterson S, El Guerche-Séblain C, Launay O; AP-PH COVIBOOST Vaccine Trial Group. Coudeville L, et al. Among authors: launay o. Vaccines (Basel). 2024 Sep 21;12(9):1079. doi: 10.3390/vaccines12091079. Vaccines (Basel). 2024. PMID: 39340109 Free PMC article.
Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants.
Chalouni M, Loubet P, Lhomme E, Ninove L, Barrou B, Blay JY, Hourmant M, de Seze J, Laville M, Laviolle B, Lelièvre JD, Morel J, Quoc SN, Spano JP, Terrier B, Thiebaut A, Viallard JF, Vrtovsnik F, Circosta S, Barquin A, Gharib M, Tartour E, Parfait B, Thiébaut R, Meyer L, de Lamballerie X, Launay O, Wittkop L; ANRS0001S COV-POPART study group. Chalouni M, et al. Among authors: launay o. BMC Infect Dis. 2024 Sep 27;24(1):1049. doi: 10.1186/s12879-024-09861-5. BMC Infect Dis. 2024. PMID: 39333909 Free PMC article.
The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 2021-2022 influenza season.
Bricout H, Levant MC, Assi N, Crépey P, Descamps A, Mari K, Gaillat J, Gavazzi G, Grenier B, Launay O, Mosnier A, Raguideau F, Watier L, Harris RC, Chit A. Bricout H, et al. Among authors: launay o. Clin Microbiol Infect. 2024 Dec;30(12):1592-1598. doi: 10.1016/j.cmi.2024.08.012. Epub 2024 Aug 24. Clin Microbiol Infect. 2024. PMID: 39187126 Free article.
Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARS-CoV-2 mRNA vaccination.
Benhamouda N, Besbes A, Bauer R, Mabrouk N, Gadouas G, Desaint C, Chevrier L, Lefebvre M, Radenne A, Roelens M, Parfait B, Weiskopf D, Sette A, Gruel N, Courbebaisse M, Appay V, Paul S, Gorochov G, Ropers J, Lebbah S, Lelievre JD, Johannes L, Ulmer J, Lebeaux D, Friedlander G, De Lamballerie X, Ravel P, Kieny MP, Batteux F, Durier C, Launay O, Tartour E. Benhamouda N, et al. Among authors: launay o. iScience. 2024 Jul 2;27(8):110441. doi: 10.1016/j.isci.2024.110441. eCollection 2024 Aug 16. iScience. 2024. PMID: 39104410 Free PMC article.
497 results